Compare CULP & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CULP | EDSA |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 51.5M |
| IPO Year | 1994 | 2018 |
| Metric | CULP | EDSA |
|---|---|---|
| Price | $3.64 | $4.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 91.3K | 73.8K |
| Earning Date | 03-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.06 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $203,482,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | $7.83 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.70 | $0.72 |
| 52 Week High | $4.75 | $20.32 |
| Indicator | CULP | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 60.01 | 29.70 |
| Support Level | $3.19 | $1.34 |
| Resistance Level | $4.02 | $5.10 |
| Average True Range (ATR) | 0.18 | 0.34 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 50.59 | 10.66 |
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.